Immuno-Biological Laboratories Co., Ltd.
(Disclosure Items Progress) Notice regarding GLP-compliant repeated dosing toxicity test of anti-HIV antibody
The animal study portion of the GLP-compliant repeated dosing toxicity test for the anti-HIV antibody related to jointly held patents has finished. The final report is being compiled by the institution, and NOAEL assessments will be confirmed after receipt and review. Going forward, consultations with PMDA and preparation for clinical trials will proceed. The impact on consolidated results for the fiscal year ending March 2026 is unknown at this time.
Key Figures
- NOAEL assessment finalization timing: after receipt and review of final report
- Preparations for clinical trial initiation: planned
- Impact on consolidated results for the fiscal year ending March 2026: Unknown
AI要約
Key points of the news
Regarding jointly held patents, the GLP-compliant repeated dosing toxicity animal study conducted by CURED has ended as planned. The final report is being compiled by the institution, and assessments such as NOAEL will be finalized after receipt and review of the report. Going forward, preparations for initiating clinical trials will proceed in coordination with CURED, including consultations with PMDA. Direct impact on consolidated results for the fiscal year ending March 2026 is unclear.
Outlook / Impact
After receipt of the final test report, contents will be reviewed and disclosed as appropriate. Preparations for initiating trials will progress in coordination with CURED. If there are matters to disclose, they will be released promptly. At this time, no financial impact is expected for the fiscal year ending March 2026, but effects may arise depending on trial progress and regulatory developments.
ACME Immunobiology Institute Limited
Company overview · Stock price · Financial data · All IR
